CDER's Woodcock says Vytorin criticism overblown

Share this article:
The press and the scientific community are “piling on” Vytorin unfairly, CDER director Janet Woodcock told the news site FDA Webview in an interview. 

“I don't know to what extent we should wade into these scientific melees,” said Woodcock. “I believe people are piling on right now on one side of the argument. Independent reporters and media, if they really want to have some reasoned approach, ought to step back from that. But what we see right now is everybody just piling on to the same message.”

Woodcock compared Vytorin critics who have raised questions about the value of LDL lowering to scientists who deviate from the conventional wisdom on global warming. “You can always find some scientist who'd say, ‘Well, it isn't exactly like that,' But they didn't mean that the client wasn't getting warmer – they just had some little nit-pick with the current model,” Woodcock said, adding that “anyone who questions the lowering of LDL cholesterol overall is probably, like Bob Temple said, trying to kill the population.”

Temple, director of the FDA's Office of Medical Policy, and FDA Office of New Drugs Director John Jenkins had previously given interviews to the site downplaying the results of the Enhance trial due to its small size and reiterating the importance of LDL lowering. 

Woodcock added: “What happens with these is that there is some little point that the scientists are arguing about, and then the media get on it, and they start throwing the baby out with the bathwater.” 
Said Bernstein's Tim Anderson in an analyst note: “All of this is important because what FDA ends up doing with Enhance (we think not much) will have influence over what payers do with Vytorin, and related product Zetia, which in turn will have an impact on what physicians/patients do with the products.”

FDA Webview is published by James Dickinson, a regular contributor to MM&M.
Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

More in News

New lipid agents are high on potency, low on doc awareness

New lipid agents are high on potency, low ...

The new PCSK9 class of cholesterol-lowering antibodies continues to look promising, but many doctors—particularly PCPs—have never even heard of the experimental drugs.

Novartis may have game-changing drug

Novartis may have game-changing drug

Key opinion leaders indicate they are ready to embrace Novartis's experimental heart failure medication LCZ696. Such a move could upend heart failure treatment protocols.

Five things for pharma marketers to know: Tuesday, September 2

Five things for pharma marketers to know: Tuesday, ...

Sanofi and Regeneron unveil Phase-III results of their PCSK9; Merck will present data on its anti-PD-1 at the end of this month; WSJ op/ed suggests US should lead fight against ...